Woodbury – January 12, 2022 – The Board members of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) have elected Michael Needham as incoming Chair of IPAC-RS. Mr. Needham will serve a six-month term as Vice Chair and on June 1, 2022, he will assume the role of Chair of the IPAC-RS Board, a two-year term. He will succeed current IPAC-RS Chair, Carla Vozone, PharmD, MBA, Vice President Strategy, Innovation and Partnerships Inhalation at Catalent Pharma Solutions, who is completing four years of leadership service to IPAC-RS and will become Chair Emeritus from June 2022-2024.

Mike Needham, BSc, MRSC, CChem, is Global Respiratory Product Development Manager at Kindeva Drug Delivery where he leads a team of scientists working on inhalation product development and science. His career in inhalation product development spans almost 30 years, primarily in the development of pMDI products and related device technologies.  Mr. Needham has broad experience working on DPIs and other related technologies and has worked both for pharmaceutical companies and CDMOs.  “I look forward to helping IPAC-RS remain the leading voice of the global orally inhaled and nasal drug product (OINDP) industry,” Needham said. “These past two years have highlighted the criticality of OINDPs and the companies that develop and manufacture these medical products. IPAC-RS will continue its important efforts to advance the global regulation and science of OINDPs and further its dedication to constructive collaboration with the broader OINDP community. I look forward to serving the IPAC-RS Board and working closely with leaders from industry, academic research institutions, and global regulatory authorities in advancement of patient care.”

Aaron Mann, Chief Executive Officer for Kindeva Drug Delivery, added. “IPAC-RS in an important organization for our industry and we are honored that Mr. Needham has been selected as the incoming Chair. We are confident that his decades of experience in the OINDP area will serve the industry well as we continue to navigate through the ever-evolving world of changing regulations as well as exciting new opportunities.”


About Kindeva Drug Delivery

Headquartered in St. Paul, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery. Kindeva employs approximately 1,000 people worldwide. For more information, visit www.kindevadd.com.


The International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) has been the leading global voice of the orally inhaled and nasal drug products (OINDP) industry for more than 20 years. Through joint research, benchmarking, collecting, and analyzing data, and developing best practices, IPAC-RS advances and supports science-based regulatory approaches for OINDP, to ensure their availability, safety, efficacy, and quality. IPAC-RS works collaboratively across the industry and with external experts from regulatory agencies, standard-setting bodies, academia, pharmacopeias, healthcare providers, patient groups, and other stakeholders. IPAC-RS members are based around the world, and their activities are global, with region-specific projects in North and South America, Europe, and Asia. IPAC-RS shares its findings with the larger scientific and regulatory community through publications, online tutorials, in-person training courses, webinars, and conferences.

Kindeva Careers

Inventive, curious, and committed to results? We’re hiring.

Explore Job Opportunities